Preclinical Evaluation of a &lt;sup&gt;177&lt;/sup&gt;Lu-Labeled Gastrin-Releasing Peptide Receptor Antagonist and Prostate Cancer Treatment with Monotherapy and in Combination with Everolimus. Here, GRPR is linked to prostate carcinoma.